STRUCTURE-BASED DEVELOPMENT OF INHIBITORS OF VIRAL CHYMOTRYPSIN-LIKE PROTEASES

基于结构的病毒胰凝乳蛋白酶样蛋白酶抑制剂的开发

• 批准号: 7598168
• 负责人: ERNST M BERGMANN
• 金额: $ 0.02万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7598168
• 关键词: Animals; Antiviral Agents; Binding; Chymase; Computer Retrieval of Information on Scientific Projects Database; Development; Endopeptidases; Enzymes; Evolution; Funding; Grant; Human; Institution; Numbers; Peptide Hydrolases; Pharmaceutical Preparations; RNA Viruses; Research; Research Personnel; Resources; Source; Specificity; Structure; United States National Institutes of Health; Viral; Virus; Virus Inhibitors; Work; base; design; inhibitor/antagonist; pathogen

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The viral chymotrypsin-like proteases of positive-sense, single-stranded RNA viruses are an ideal target for the design of antiviral drugs. The enzymes have a unique mechanism and most have a cleavage specificity that is different from that of all known mammalian proteases. The viral proteases are also absolutely required for viral replication. Many important pathogens of humans and animals belong to this group of viruses. We and others have determined crystal structures of a number of viral chymotrypsin-like proteases, including some with bound inhibitors. This work is valuable for the understanding of viral evolution, enzymatic mechanisms and the development of anti viral drugs. We are pursuing a project to develop different and more effective inhibitors of several different viral proteases.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构为 研究中心，而研究中心不一定是研究者所在的机构。 正链RNA病毒的胰凝乳蛋白酶样蛋白酶是设计抗病毒药物的理想靶点。这些酶具有独特的机制，并且大多数具有不同于所有已知哺乳动物蛋白酶的切割特异性。病毒蛋白酶也是病毒复制所必需的。人类和动物的许多重要病原体都属于这类病毒。我们和其他人已经确定了一些病毒胰凝乳蛋白酶样蛋白酶的晶体结构，包括一些结合抑制剂。这一工作对于理解病毒进化、酶促机制和开发抗病毒药物具有重要意义。我们正在进行一个项目，以开发不同的和更有效的抑制剂的几种不同的病毒蛋白酶。